Milestone Pharmaceuticals Inc. 8-K

What Happened
Milestone Pharmaceuticals Inc. (MIST) announced its financial results for the fourth quarter and fiscal year ended December 31, 2025 and provided an update on the commercial launch of CARDAMYST™ (etripamil) Nasal Spray for the treatment of PSVT. The company issued a press release on March 20, 2026 (furnished as Exhibit 99.1 to the Form 8‑K) that summarizes those quarterly and year‑end results and the launch progress.

Key Details

• Filing date: March 20, 2026 — Form 8‑K Item 2.02 (Results of Operations and Financial Condition).
• Period covered: fourth quarter and fiscal year ended December 31, 2025.
• Commercial update: press release includes progress on the commercial launch of CARDAMYST™ (etripamil) Nasal Spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
• Exhibit: Press release is furnished as Exhibit 99.1 (Item 9.01 also notes the Inline XBRL cover page tags).

Why It Matters
Earnings and year‑end financial results are material events that can affect Milestone’s stock price and investor expectations; the added update on CARDAMYST’s commercial launch is particularly relevant because product commercialization is a key potential driver of revenue growth. Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial figures, any commentary on revenue, cash position, guidance or launch metrics, and watch for any subsequent filings (e.g., quarterly reports) that provide audited financial statements and more detail.